Evidence map›Paper›PMID 32573895›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society2020

SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region.

Federica Maritati, Elisabetta Cerutti, Lina Zuccatosta, Alessandro Fiorentini, Carolina Finale, Marta Ficosecco, Fabrizio Cristiano, Alessandro Capestro, Emilio Balestra, Domenica Taruscia and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis.Transplant infectious disease : an official journal of the Transplantation Society · 2021
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region.Transplant infectious disease : an official journal of the Transplantation Society · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Federica MaritatiNephrology, Dialysis and Renal Transplantation Unit, Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi of Ancona, Ancona, Italy.
Elisabetta CeruttiAnesthesia and Transplant Surgical Intensive Care Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.
Lina ZuccatostaOperative Unit of Pneumology, Ospedali Riuniti University Hospital, Ancona, Italy.
Alessandro FiorentiniInfectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
Carolina FinaleNephrology, Dialysis and Renal Transplantation Unit, Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi of Ancona, Ancona, Italy.
Marta FicoseccoAnesthesia and Intensive Care Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.
Fabrizio CristianoItalian Civil Protection Department for Covid-19 Emergency, Nephrology and Dialysis Unit, Ospedale "San Pio da Pietrelcina", Vasto Chieti, Italy.
Alessandro CapestroDepartment of Paediatric and Congenital Cardiac Surgery and Cardiology, Ospedali Riuniti, Ancona, Italy.
Emilio BalestraNephrology, Dialysis and Renal Transplantation Unit, Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi of Ancona, Ancona, Italy.
Domenica TarusciaNephrology, Dialysis and Renal Transplantation Unit, Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi of Ancona, Ancona, Italy.
Marco VivarelliHepatobiliary and Abdominal Transplantation Surgery, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.
Abele DonatiAnesthesia and Intensive Care Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.
Gian Piero PernaCardiovascular Science Department, Cardiology and Coronary Care Unit, Ospedali Riuniti di Ancona, Ancona, Italy.
Andrea GiacomettiInfectious Diseases Clinic, Department of Biological Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
Marcello TavioUnit of Emerging and Immunosuppressed Infectious Diseases, Department of Gastroenterology and Transplantation, Polytechnic University of Marche, Ancona, Italy.
Maicol OnestaInternal Medicine Unit, Ospedale di Fabriano, Fabriano Ancona, Italy.
Laura Di SanteUnit of Virology, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Andrea RanghinoNephrology, Dialysis and Renal Transplantation Unit, Azienda Ospedaliera Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi of Ancona, Ancona, Italy.ORCID https://orcid.org/0000-0002-6976-7539

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfection related to Coronavirus-19 (CoV-2) is pandemic affecting more than 4 million people in 187 countries worldwide. By May 10, 2020, it caused more than 280 000 deaths all over the world. Preliminary data reported a high prevalence of CoV-2 infection and mortality due to severe acute respiratory syndrome related CoV-2 (SARS-CoV-2) in kidney-transplanted patients (KTRs). Nevertheless, the outcomes and the best treatments for SARS-CoV-2-affected KTRs remain unclear.

methodsIn this report, we describe the clinical data, the treatments, and the outcomes of 5 KTRs with SARS-CoV-2 admitted to our hospital in Ancona, Marche region, Italy, from March 17 to present. Due to the severity of SARS-CoV-2, immunosuppression with calcineurin inhibitors, antimetabolites, and mTOR-inhibitors were stopped at the admission. All KTRs were treated with low-dose steroids. 4/5 KTRs were treated with hydroxychloroquine. All KTRs received tocilizumab up to one dose.

resultsOverall, the incidence of SARS-CoV-2 in KTRs in the Marche region was 0.85%. 3/5 were admitted in ICU and intubated. One developed AKI with the need of CRRT with Cytosorb. At present, two patients died, two patients were discharged, and one is still inpatient in ICU.

conclusionsThe critical evaluation of all cases suggests that the timing of the administration of tocilizumab, an interleukin-6 receptor antagonist, could be associated with a better efficacy when administered in concomitance to the drop of the oxygen saturation. Thus, in SARS-CoV-2-affected KTRs, a close biochemical and clinical monitoring should be set up to allow physicians to hit the virus in the right moment such as a sudden reduction of the oxygen saturation and/or a significant increase in the laboratory values such as D-dimer.

Indexed as

Acute Kidney InjuryAgedAntibodies, Monoclonal, HumanizedAntiviral AgentsCOVID-19Drug Therapy, CombinationExtracorporeal Membrane OxygenationFemaleGraft RejectionHumansHydroxychloroquineImmunocompromised HostImmunosuppressive AgentsIncidenceItalyKidney TransplantationAntibodies, Monoclonal, HumanizedAntiviral AgentsHydroxychloroquineImmunosuppressive AgentsOxygentocilizumabCytosorbkidney transplantSARS-CoV-2tocilizumab

Identifiers

PMID32573895
PMCPMC7361066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.